Penpulimab (Anniko)
Revision as of 20:54, 9 June 2023 by Warner-admin (talk | contribs) (Text replacement - "[[Hodgkin lymphoma|" to "[[Classical Hodgkin lymphoma|")
Note: Penpulimab is approved in China, but does not appear to have a brand name at this time.
Mechanism of action
PD-1 inhibitor
Diseases for which it is used
History of changes in NMPA indication
- 2021-08-05: Approved for treatment of patients with relapsed or refractory ("r/r") classic Hodgkin’s lymphoma ("cHL") after at least second-line systemic chemotherapy treatment.
Also known as
- Code name: AK105